[96a5a0]: / output / allTrials / identified / NCT00795301_identified.json

Download this file

642 lines (642 with data), 29.2 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
{
"info": {
"nct_id": "NCT00795301",
"official_title": "A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.",
"inclusion_criteria": "1. All patients must have histologically or cytologically confirmed T3/4 and/or node positive adenocarcinoma of the rectum with the inferior border within 12 cm from the anal verge without evidence of distant metastases, as evaluated by computed tomography, ultrasonography, MRI or clinically.\n2. Patients must have normal organ and marrow function as defined below:\n\n leukocytes >3,000/mcL absolute neutrophil count >1,500/mcL platelets >100,000/mcL total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT) greater than 2.5 X institutional upper limit of normal creatinine within normal institutional limits\n3. Age >21 years\n4. Patients must have ECOG performance status of 0-2.\n5. Patients must be 18 years old or greater.\n6. The tumor must be considered by the surgeon to be amenable to curative resection.\n7. Ability to understand and the willingness to sign a written informed consent document.\n8. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
"exclusion_criteria": "1. Patients who have had prior chemotherapy or radiotherapy.\n2. Patients may not be receiving any other investigational agents.\n3. Patients with stage I or IV cancer of the rectum.\n4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab, oxaliplatin or capecitabine.\n5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n6. Inability to take oral medications.\n7. Pregnant women are excluded from this study because agents use in the study may cause fetal harm.\n8. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with docetaxel. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.\n9. History of other malignancies within 5 years, except non-melanoma skin cancer, in situ carcinoma of the cervix or ductal carcinoma of the breast. Previous invasive cancer permitted if disease-free at least 5 years.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. All patients must have histologically or cytologically confirmed T3/4 and/or node positive adenocarcinoma of the rectum with the inferior border within 12 cm from the anal verge without evidence of distant metastases, as evaluated by computed tomography, ultrasonography, MRI or clinically.",
"criterions": [
{
"exact_snippets": "histologically or cytologically confirmed T3/4 and/or node positive adenocarcinoma of the rectum",
"criterion": "adenocarcinoma of the rectum",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": [
"histologically",
"cytologically"
]
},
{
"requirement_type": "stage",
"expected_value": [
"T3",
"T4"
]
},
{
"requirement_type": "node involvement",
"expected_value": "positive"
}
]
},
{
"exact_snippets": "inferior border within 12 cm from the anal verge",
"criterion": "inferior border of the tumor",
"requirements": [
{
"requirement_type": "location",
"expected_value": {
"operator": "<=",
"value": 12,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "without evidence of distant metastases",
"criterion": "distant metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "evaluated by computed tomography, ultrasonography, MRI or clinically",
"criterion": "evaluation methods",
"requirements": [
{
"requirement_type": "methods",
"expected_value": [
"computed tomography",
"ultrasonography",
"MRI",
"clinically"
]
}
]
}
]
},
{
"line": "2. Patients must have normal organ and marrow function as defined below:",
"criterions": [
{
"exact_snippets": "normal organ and marrow function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "normal"
}
]
},
{
"exact_snippets": "normal organ and marrow function",
"criterion": "marrow function",
"requirements": [
{
"requirement_type": "functionality",
"expected_value": "normal"
}
]
}
]
},
{
"line": "leukocytes >3,000/mcL absolute neutrophil count >1,500/mcL platelets >100,000/mcL total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT) greater than 2.5 X institutional upper limit of normal creatinine within normal institutional limits",
"criterions": [
{
"exact_snippets": "leukocytes >3,000/mcL",
"criterion": "leukocytes",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 3000,
"unit": "mcL"
}
}
]
},
{
"exact_snippets": "absolute neutrophil count >1,500/mcL",
"criterion": "absolute neutrophil count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 1500,
"unit": "mcL"
}
}
]
},
{
"exact_snippets": "platelets >100,000/mcL",
"criterion": "platelets",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">",
"value": 100000,
"unit": "mcL"
}
}
]
},
{
"exact_snippets": "total bilirubin within normal institutional limits",
"criterion": "total bilirubin",
"requirements": [
{
"requirement_type": "level",
"expected_value": "within normal institutional limits"
}
]
},
{
"exact_snippets": "AST(SGOT)/ALT(SGPT) greater than 2.5 X institutional upper limit of normal",
"criterion": "AST(SGOT)/ALT(SGPT)",
"requirements": [
{
"requirement_type": "level",
"expected_value": "greater than 2.5 X institutional upper limit of normal"
}
]
},
{
"exact_snippets": "creatinine within normal institutional limits",
"criterion": "creatinine",
"requirements": [
{
"requirement_type": "level",
"expected_value": "within normal institutional limits"
}
]
}
]
},
{
"line": "3. Age >21 years",
"criterions": [
{
"exact_snippets": "Age >21 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 21,
"unit": "years"
}
}
]
}
]
},
{
"line": "4. Patients must have ECOG performance status of 0-2.",
"criterions": [
{
"exact_snippets": "ECOG performance status of 0-2",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "5. Patients must be 18 years old or greater.",
"criterions": [
{
"exact_snippets": "Patients must be 18 years old or greater.",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "6. The tumor must be considered by the surgeon to be amenable to curative resection.",
"criterions": [
{
"exact_snippets": "tumor must be considered by the surgeon to be amenable to curative resection",
"criterion": "tumor",
"requirements": [
{
"requirement_type": "amenability to curative resection",
"expected_value": true
}
]
}
]
},
{
"line": "7. Ability to understand and the willingness to sign a written informed consent document.",
"criterions": [
{
"exact_snippets": "Ability to understand",
"criterion": "cognitive ability",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "willingness to sign a written informed consent document",
"criterion": "willingness to consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "8. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.",
"criterions": [
{
"exact_snippets": "Women of child-bearing potential",
"criterion": "women of child-bearing potential",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "men must agree to use adequate contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "agreement",
"expected_value": true
}
]
},
{
"exact_snippets": "(hormonal or barrier method of birth control; abstinence)",
"criterion": "contraception method",
"requirements": [
{
"requirement_type": "type",
"expected_value": [
"hormonal",
"barrier",
"abstinence"
]
}
]
},
{
"exact_snippets": "prior to study entry and for the duration of study participation",
"criterion": "contraception duration",
"requirements": [
{
"requirement_type": "time period",
"expected_value": "prior to study entry and for the duration of study participation"
}
]
},
{
"exact_snippets": "Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately",
"criterion": "pregnancy during study",
"requirements": [
{
"requirement_type": "action",
"expected_value": "inform treating physician immediately"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 21 Years",
"criterions": [
{
"exact_snippets": "minimum age of 21 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 21,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Patients who have had prior chemotherapy or radiotherapy.",
"criterions": [
{
"exact_snippets": "Patients who have had prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Patients who have had prior ... radiotherapy",
"criterion": "prior radiotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. Patients may not be receiving any other investigational agents.",
"criterions": [
{
"exact_snippets": "Patients may not be receiving any other investigational agents.",
"criterion": "investigational agents",
"requirements": [
{
"requirement_type": "receiving",
"expected_value": false
}
]
}
]
},
{
"line": "3. Patients with stage I or IV cancer of the rectum.",
"criterions": [
{
"exact_snippets": "stage I or IV cancer of the rectum",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"I",
"IV"
]
}
]
},
{
"exact_snippets": "cancer of the rectum",
"criterion": "cancer location",
"requirements": [
{
"requirement_type": "location",
"expected_value": "rectum"
}
]
}
]
},
{
"line": "4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab, oxaliplatin or capecitabine.",
"criterions": [
{
"exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab, oxaliplatin or capecitabine.",
"criterion": "allergic reactions to similar compounds",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
"criterions": [
{
"exact_snippets": "Uncontrolled intercurrent illness ... ongoing or active infection",
"criterion": "ongoing or active infection",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... symptomatic congestive heart failure",
"criterion": "symptomatic congestive heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... unstable angina pectoris",
"criterion": "unstable angina pectoris",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... cardiac arrhythmia",
"criterion": "cardiac arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Uncontrolled intercurrent illness ... psychiatric illness/social situations that would limit compliance with study requirements",
"criterion": "psychiatric illness/social situations",
"requirements": [
{
"requirement_type": "impact on compliance",
"expected_value": false
}
]
}
]
},
{
"line": "6. Inability to take oral medications.",
"criterions": [
{
"exact_snippets": "Inability to take oral medications.",
"criterion": "ability to take oral medications",
"requirements": [
{
"requirement_type": "ability",
"expected_value": false
}
]
}
]
},
{
"line": "7. Pregnant women are excluded from this study because agents use in the study may cause fetal harm.",
"criterions": [
{
"exact_snippets": "Pregnant women are excluded",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "8. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with docetaxel. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.",
"criterions": [
{
"exact_snippets": "HIV-positive patients",
"criterion": "HIV status",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "on combination antiretroviral therapy",
"criterion": "combination antiretroviral therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "9. History of other malignancies within 5 years, except non-melanoma skin cancer, in situ carcinoma of the cervix or ductal carcinoma of the breast. Previous invasive cancer permitted if disease-free at least 5 years.",
"criterions": [
{
"exact_snippets": "History of other malignancies within 5 years",
"criterion": "history of other malignancies",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
},
{
"exact_snippets": "except non-melanoma skin cancer",
"criterion": "non-melanoma skin cancer",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "in situ carcinoma of the cervix",
"criterion": "in situ carcinoma of the cervix",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "ductal carcinoma of the breast",
"criterion": "ductal carcinoma of the breast",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": true
}
]
},
{
"exact_snippets": "Previous invasive cancer permitted if disease-free at least 5 years",
"criterion": "previous invasive cancer",
"requirements": [
{
"requirement_type": "disease-free period",
"expected_value": {
"operator": ">=",
"value": 5,
"unit": "years"
}
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}